Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double‐blind controlled study in general practice

@article{Nguyen2006EfficacyOE,
  title={Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double‐blind controlled study in general practice},
  author={Nhan Nguyen and E. Fakra and Vincent Pradel and Elisabeth Jouve and Christine Alquier and Marie-Emmanuelle Le Guern and Jo{\"e}lle Micallef and Olivier Blin},
  journal={Human Psychopharmacology: Clinical and Experimental},
  year={2006},
  volume={21}
}
  • N. Nguyen, E. Fakra, O. Blin
  • Published 1 April 2006
  • Psychology, Medicine
  • Human Psychopharmacology: Clinical and Experimental
Adjustment Disorders With Anxiety (ADWA) account for almost 10% of psychologically motivated consultations in primary care. The aim of this double‐blind randomised parallel group study was to compare (non‐inferiority test) the efficacies of etifoxine, a non‐benzodiazepine anxiolytic drug, and lorazepam, a benzodiazepine, for ADWA outpatients followed by general practitioners. 191 outpatients (mean age: 43, female: 66%) were assigned to receive etifoxine (50 mg tid) or lorazepam (0.5‐0.5‐1 mg… 
Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial.
TLDR
Etifoxine was non-inferior to clonazepam on reduction of anxiety symptoms, adverse effects, and clinical improvement, and a sensitivity analysis of the results was conducted.
Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial
TLDR
This randomized controlled trial provides support for the efficacy and safety of etifoxine in the management of adjustment disorder with anxiety, particularly when treatment discontinuation data are also assessed.
Adjustment disorder with anxiety: Care practice
  • D. Stein
  • Medicine, Psychology
    European Psychiatry
  • 2015
Efficacy of etifoxine versus phenazepam in the treatment of patients with adjustment disorders (open randomized controlled trial)
In the article, based on the study of 90 patients with symptoms of adjustment disorders, the results indicate a pronounced anxiolytic effect of etifoxine in the absence of a benzodiazepine-type
[Remote consequences of the long-term uncontrollable consumption of anxiolytics and hypnotics in elderly: a problem of drug dependence].
TLDR
An analysis of risk factors for this disease in elderly demonstrated the higher risk in patients aged ≤ 60 years and in those who used diazepam, the risk was higher in patients who preferred phenazepam.
An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action
TLDR
Its dual mechanisms of action in anxiety and the positive data yielded by clinical trials support the use of etifoxine for treating the anxiety signs and symptoms of individuals with ADs.
[Remote consequences of the long-term uncontrolled use of anxiolytic and hypnotic drugs by elderly patients: cognitive disorders].
TLDR
The duration of a mental disorder and duration of uncontrollable consumption of anxiolytics and hypnotics did not exert an effect on the development and reversibility of cognitive impairment and a combination of anxIOlytics with alcohol increased the risk of dementia and did not reverse the cognitive pathology.
Etifoxine for Pain Patients with Anxiety
TLDR
It seems promising that non-benzodiazepine anxiolytics including etifoxine will replenish shortcomings of benzodiazepines and selective serotonin reuptake inhibitors according to animated studies related to TSPO.
Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice
TLDR
In conclusion, adjustment disorder with anxiety seems to be effectively managed by an alternative and safer solution than benzodiazepines, with limited side effects and a negligible rebound effect.
...
...

References

SHOWING 1-10 OF 60 REFERENCES
[Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study].
TLDR
Results show the interest of using etifoxine in the treatment of adjustment disorder with anxiety and should be confirmed by further studies.
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
TLDR
A demonstration of similar effectiveness and superior safety would favor buspirone in the treatment of generalized anxiety disorder.
Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
TLDR
A demonstration of similar effectiveness and superior safety would favor buspirone in the treatment of generalized anxiety disorder.
[Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
TLDR
Clobazam like lorazepam improved anxiety more quickly than buspirone; after 3 weeks of therapy, efficacy was comparable with the 3 drugs and persisted after treatment discontinuation.
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
TLDR
This first placebo-controlled demonstration of the long-term efficacy of any drug class in treating outpatients with DSM-IV-diagnosed GAD shows venlafaxine XR is an effective, rapidly acting, safe, once-daily agent for both the short- and long- term treatment of anxiety and may provide an important alternative to currently available anxiolytics.
Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients
TLDR
Both buspirone and lorazepam were more efficacious in reducing anxiety symptoms than placebo during the treatment and taper period; however, in contrast to the active drugs, patients of the placebo group showed further clinical improvement during the control period, especially in the HAM-A score, so differences between placebo and active drugs became smaller at the end of the study.
Bromazepam and lorazepam in generalized anxiety: a placebo‐controlled study with measurement of drug plasma concentrations
TLDR
Drug‐treated patients had consistently less cognitive impairment than those treated with placebo, the difference being statistically significant in the case of bromazepam, and the most frequent side‐effects reported with each drug were drowsiness and depression, which tended to emerge toward the end of the 4‐week period.
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam
  • M. Bourin, M. Malinge
  • Psychology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1995
Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial.
TLDR
Clinical improvement data showed gepirone's anxiolytic response to be delayed, being significant from placebo beginning at week 6, whereas diazepam caused significantly more relief than placebo from week 1 onward, and taper results showed that onlydiazepam, but not gepIRone, caused a temporary worsening of anxiety symptoms or rebound.
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation.
TLDR
A short half-life and higher daily doses were associated with greater withdrawal severity, as were personality traits, such as dependency and neuroticism, less education and higher baseline levels of anxious and depressive symptoms.
...
...